The National Screening Unit is hosting two sessions on the science behind the plan to introduce HPV testing as the primary screening test in the National Cervical Screening Programme in New Zealand.
The first session will be held in Christchurch on Thursday 13 October 2016 from 5.30pm to 7.30 pm, and will be repeated at a second session in Auckland on Friday 14 October 2016 from 12noon to 3.00 pm.
Thursday 13 October 2016 Christchurch 5.30 – 7.30 pm
Venue: Rolleston Lecture Theatre, School of Medicine, Otago University, 2 Riccarton Avenue, Christchurch
Friday 14 October 2016 Auckland 12 noon – 3.30 pm
Venue: CEC, Level 5, Building 32, Auckland City Hospital, Park Rd, Auckland
The sessions will include expert speakers from New Zealand and Australia, followed by a Q&A panel discussion.
Dr Jane O’Hallahan, Clinical Director National Screening Unit - Benefits and harms of screening
Dr Karen Canfell, Director of Research, Cancer Research Division, Cancer Council NSW - The science behind NZ’s decision to change to Primary HPV Testing
Dr Marion Saville, Chairperson HPV Testing for Primary Screening Project – Compass trial leading the way
Dr Margaret Sage, Clinical Leader Pathology, National Cervical Screening Programme - The ARTISTIC trial (UK). Putting invasive cancer in perspective
Dr Gary Fentiman, Clinical Leader Colposcopy, National Cervical Screening Programme - Responding to your concerns
The sessions are open to everyone with an interest in HPV testing as the primary screening test in the National Cervical Screening Programme.
Where can I contact the organiser with any questions?
Please direct any queries by email to email@example.com